Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.35
NYSE:MDT's Cash to Debt is ranked lower than
82% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. NYSE:MDT: 0.35 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:MDT' s Cash to Debt Range Over the Past 10 Years
Min: 0.15  Med: 0.6 Max: 9.58
Current: 0.35
0.15
9.58
Equity to Asset 0.51
NYSE:MDT's Equity to Asset is ranked lower than
67% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NYSE:MDT: 0.51 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:MDT' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.57 Max: 0.82
Current: 0.51
0.37
0.82
Interest Coverage 4.19
NYSE:MDT's Interest Coverage is ranked lower than
87% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 73.78 vs. NYSE:MDT: 4.19 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:MDT' s Interest Coverage Range Over the Past 10 Years
Min: 3.82  Med: 10.69 Max: 16.28
Current: 4.19
3.82
16.28
F-Score: 6
Z-Score: 2.63
M-Score: -2.46
WACC vs ROIC
7.82%
7.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.65
NYSE:MDT's Operating margin (%) is ranked higher than
87% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. NYSE:MDT: 18.65 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:MDT' s Operating margin (%) Range Over the Past 10 Years
Min: 16.71  Med: 23.03 Max: 30.17
Current: 18.65
16.71
30.17
Net-margin (%) 14.62
NYSE:MDT's Net-margin (%) is ranked higher than
84% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. NYSE:MDT: 14.62 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:MDT' s Net-margin (%) Range Over the Past 10 Years
Min: 12.27  Med: 18.81 Max: 22.78
Current: 14.62
12.27
22.78
ROE (%) 8.28
NYSE:MDT's ROE (%) is ranked higher than
64% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. NYSE:MDT: 8.28 )
Ranked among companies with meaningful ROE (%) only.
NYSE:MDT' s ROE (%) Range Over the Past 10 Years
Min: 6.72  Med: 19.6 Max: 27.52
Current: 8.28
6.72
27.52
ROA (%) 4.21
NYSE:MDT's ROA (%) is ranked higher than
65% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. NYSE:MDT: 4.21 )
Ranked among companies with meaningful ROA (%) only.
NYSE:MDT' s ROA (%) Range Over the Past 10 Years
Min: 3.43  Med: 10.42 Max: 14.3
Current: 4.21
3.43
14.3
ROC (Joel Greenblatt) (%) 60.16
NYSE:MDT's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. NYSE:MDT: 60.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:MDT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 51.21  Med: 66.98 Max: 82.85
Current: 60.16
51.21
82.85
Revenue Growth (3Y)(%) 7.80
NYSE:MDT's Revenue Growth (3Y)(%) is ranked higher than
68% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. NYSE:MDT: 7.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:MDT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.2  Med: 12.6 Max: 17.9
Current: 7.8
4.2
17.9
EBITDA Growth (3Y)(%) 4.10
NYSE:MDT's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. NYSE:MDT: 4.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:MDT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.5  Med: 9.6 Max: 24
Current: 4.1
-15.5
24
EPS Growth (3Y)(%) -9.70
NYSE:MDT's EPS Growth (3Y)(%) is ranked lower than
70% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NYSE:MDT: -9.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:MDT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.7  Med: 13.5 Max: 27.1
Current: -9.7
-9.7
27.1
» NYSE:MDT's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-11-22)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MDT Guru Trades in Q4 2015

Louis Moore Bacon 375,000 sh (New)
First Eagle Investment 1,940,036 sh (+10839.02%)
Manning & Napier Advisors, Inc 5,016,210 sh (+87.74%)
Pioneer Investments 4,269,571 sh (+74.13%)
David Carlson 900,000 sh (+8.43%)
John Buckingham 22,788 sh (+7.80%)
Vanguard Health Care Fund 20,081,233 sh (unchged)
John Hussman 175,000 sh (unchged)
Ruane Cunniff 5,075 sh (unchged)
Bill Nygren 4,190,000 sh (unchged)
Ronald Muhlenkamp Sold Out
Jim Simons Sold Out
Jeff Auxier 139,273 sh (-0.14%)
PRIMECAP Management 15,187,651 sh (-0.48%)
Ken Fisher 5,905 sh (-0.57%)
Diamond Hill Capital 3,436,197 sh (-0.87%)
Mairs and Power 3,143,155 sh (-0.91%)
Dodge & Cox 6,867,935 sh (-1.48%)
Barrow, Hanley, Mewhinney & Strauss 30,282,119 sh (-2.21%)
Ray Dalio 53,186 sh (-6.99%)
Steven Cohen 461,800 sh (-7.81%)
Mario Gabelli 40,111 sh (-12.95%)
Robert Olstein 108,000 sh (-19.40%)
HOTCHKIS & WILEY 3,880,914 sh (-26.64%)
Jeremy Grantham 4,545,540 sh (-36.84%)
Keeley Asset Management Corp 25,281 sh (-37.61%)
Joel Greenblatt 2,705 sh (-73.60%)
Paul Tudor Jones 3,200 sh (-97.89%)
» More
Q1 2016

MDT Guru Trades in Q1 2016

George Soros 11,100 sh (New)
Signature Select Canadian Fund 126,900 sh (New)
Manning & Napier Advisors, Inc 7,795,870 sh (+55.41%)
Pioneer Investments 4,619,992 sh (+8.21%)
David Carlson 930,000 sh (+3.33%)
John Buckingham 23,323 sh (+2.35%)
Jeff Auxier 139,773 sh (+0.36%)
PRIMECAP Management 15,196,981 sh (+0.06%)
John Hussman 175,000 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Dodge & Cox 6,838,035 sh (-0.44%)
Mairs and Power 3,017,700 sh (-3.99%)
First Eagle Investment 1,833,793 sh (-5.48%)
Mario Gabelli 37,877 sh (-5.57%)
Vanguard Health Care Fund 18,332,133 sh (-8.71%)
Barrow, Hanley, Mewhinney & Strauss 27,494,507 sh (-9.21%)
Robert Olstein 96,000 sh (-11.11%)
Ken Fisher 5,018 sh (-15.02%)
Jeremy Grantham 3,706,658 sh (-18.46%)
Ruane Cunniff 3,895 sh (-23.25%)
Diamond Hill Capital 2,515,263 sh (-26.80%)
HOTCHKIS & WILEY 2,374,011 sh (-38.83%)
Bill Nygren 2,490,000 sh (-40.57%)
Keeley Asset Management Corp 12,172 sh (-51.85%)
» More
Q2 2016

MDT Guru Trades in Q2 2016

T Rowe Price Equity Income Fund 750,000 sh (New)
Jim Simons 573,141 sh (New)
Joel Greenblatt 167,825 sh (New)
Paul Tudor Jones 4,000 sh (New)
Steven Cohen 125,000 sh (New)
Jeremy Grantham 4,444,824 sh (+19.91%)
Pioneer Investments 4,975,460 sh (+7.69%)
Vanguard Health Care Fund 19,159,633 sh (+4.51%)
David Carlson 930,000 sh (unchged)
Bill Nygren 2,490,000 sh (unchged)
George Soros Sold Out
Jeff Auxier 139,173 sh (-0.43%)
Mairs and Power 2,994,818 sh (-0.76%)
PRIMECAP Management 14,981,004 sh (-1.42%)
Diamond Hill Capital 2,470,305 sh (-1.79%)
Dodge & Cox 6,452,264 sh (-5.64%)
Ken Fisher 4,716 sh (-6.02%)
John Buckingham 21,869 sh (-6.23%)
Keeley Asset Management Corp 11,133 sh (-8.54%)
Manning & Napier Advisors, Inc 7,062,815 sh (-9.40%)
Mario Gabelli 34,285 sh (-9.48%)
Ruane Cunniff 3,395 sh (-12.84%)
Barrow, Hanley, Mewhinney & Strauss 21,090,262 sh (-23.29%)
John Hussman 125,000 sh (-28.57%)
HOTCHKIS & WILEY 1,653,662 sh (-30.34%)
Robert Olstein 66,000 sh (-31.25%)
First Eagle Investment 1,106,014 sh (-39.69%)
» More
Q3 2016

MDT Guru Trades in Q3 2016

Ray Dalio 31,000 sh (New)
Samuel Isaly 665,629 sh (New)
Ken Fisher 4,949 sh (+4.94%)
Jeremy Grantham 4,593,000 sh (+3.33%)
Paul Tudor Jones 4,100 sh (+2.50%)
T Rowe Price Equity Income Fund 750,000 sh (unchged)
John Hussman 125,000 sh (unchged)
David Carlson 930,000 sh (unchged)
Keeley Asset Management Corp 11,133 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Jeff Auxier 139,123 sh (-0.04%)
Mairs and Power 2,960,586 sh (-1.14%)
Vanguard Health Care Fund 18,747,933 sh (-2.15%)
PRIMECAP Management 14,482,669 sh (-3.33%)
Diamond Hill Capital 2,385,913 sh (-3.42%)
Pioneer Investments 4,769,969 sh (-4.13%)
Manning & Napier Advisors, Inc 6,658,775 sh (-5.72%)
Barrow, Hanley, Mewhinney & Strauss 19,033,448 sh (-9.75%)
Ruane Cunniff 3,000 sh (-11.63%)
Dodge & Cox 5,584,858 sh (-13.44%)
Mario Gabelli 26,273 sh (-23.37%)
Robert Olstein 48,432 sh (-26.62%)
John Buckingham 16,032 sh (-26.69%)
HOTCHKIS & WILEY 1,012,932 sh (-38.75%)
Bill Nygren 1,140,000 sh (-54.22%)
First Eagle Investment 397,038 sh (-64.10%)
Jim Simons 191,241 sh (-66.63%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:ABT, NYSE:SYK, NYSE:BSX, NAS:ISRG, NYSE:STJ, NYSE:ZBH, NYSE:EW, OTCPK:SNNUF, NYSE:VAR, OTCPK:SONVY, NAS:ALGN, NYSE:TFX, OTCPK:CHEOY, NAS:ABMD, OTCPK:EKTAY, NAS:NUVA, NAS:IART, NAS:MASI, NAS:LIVN, NYSE:NVRO » details
Traded in other countries:MDT.Argentina, MDTC34.Brazil, 2M6.Germany, MDT N.Mexico, MDT.Switzerland, 0QYG.UK,
Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in three operating segments that manufacture and sell device-based medical therapies.

Medtronic PLC was founded in 1949, incorporated as a Minnesota corporation in 1957. The Company is a medical technology company - alleviating pain, restoring health, and extending life for millions of people around the world. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat and diabetes conditions. The Company functions in four operating segments that manufacture and sell device-based medical therapies: Cardiac and Vascular Group; Minimally Invasive Therapies Group; Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group includes Cardiac Rhythm Disease Management that develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRDM devices, and an integrated health solutions business; Coronary which includes therapies to treat coronary artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, including a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories; The Structural Heart business offers a comprehensive line of products and therapies to treat a variety of heart valve disorders. The Endovascular business is comprised of a comprehensive line of products and therapies to treat aortic disease (such as aneurysms, dissections, and transections) as well as peripheral vascular disease (PVD). Its products include endovascular stent graft systems, peripheral stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart. The Minimally Invasive Therapies Group is composed of the Surgical Solutions and Patient Monitoring & Recovery divisions. With a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications, the group looks to enhance patient outcomes through minimally invasive solutions. The Restorative Therapies Group includes Spine business which develops, manufactures, and markets a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its products and therapies treat a variety of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumors, fractures of the spine, and stenosis. Its Spine business also provides biologic solutions for the orthopedic and dental markets. Its Neuromodulation business includes implantable neurostimulation and targeted drug delivery systems for the management of ch

Guru Investment Theses on Medtronic PLC

Gabelli Funds Comments on Medtronic Plc - Aug 04, 2016

Medtronic plc (NYSE:MDT) (1.7%) (MDT – $75.00 – NYSE) cemented its position as the largest manufacturer of medical devices in the world with last year’s $50 billion acquisition of Covidien. This deal, structured as a tax inversion, should both improve the company’s growth rate and give it better access to its global cash flow. Meanwhile, Medtronic is accelerating its own growth rate through improved management execution and a full pipeline of new heart valves, drug coated balloons, and defibrillators. Medtronic will be the partner of choice for hospitals going forward, and the Covidien deal will allow the company to continue to return at least 50% of its cash flow to shareholders via share buybacks and dividends.



From the Gabelli Dividend Growth Fund second quarter 2016 commentary.



Check out Mario Gabelli latest stock trades

Top Ranked Articles about Medtronic PLC

Medtronic Misses 2nd Quarter Revenue Expectations Medical device company releases second-quarter earnings
Medtronic PLC (NYSE:MDT) released the results of the second quarter of 2017 on Nov. 22. The medical technology and services company headquartered in Dublin, Ireland, and traded on the NYSE reported non-GAAP diluted earnings per share of $1.12, beating analysts’ expectations by one cent, generating a surprise of only 0.90%. Read more...
Samuel Isaly Makes 9 New Buys in 3rd Quarter 5 acquisitions have impacts greater than 2% on portfolio
Samuel Isaly (Trades, Portfolio) of Eaton Vance Worldwide Health Sciences Fund acquired nine new holdings in the third quarter ended Aug. 31. Five of the holdings had impacts greater than 2% on the portfolio. Read more...
Barrow, Hanley, Mewhinney & Strauss Reduces Stakes in 2nd Quarter Guru sells shares in Honeywell, Ford, Johnson & Johnson
Barrow, Hanley, Mewhinney & Strauss trimmed existing stakes in six of its top 10 transactions in the second quarter. Read more...
Dividend Aristocrat Correlation Pairs A look at how to pair investment ideas
On June 27, I published an article discussing pairing Dividend Aristocrats based on their correlations. Read more...
Gabelli Funds Comments on Medtronic Plc Guru stock highlight
Medtronic plc (NYSE:MDT) (1.7%) (MDT – $75.00 – NYSE) cemented its position as the largest manufacturer of medical devices in the world with last year’s $50 billion acquisition of Covidien. This deal, structured as a tax inversion, should both improve the company’s growth rate and give it better access to its global cash flow. Meanwhile, Medtronic is accelerating its own growth rate through improved management execution and a full pipeline of new heart valves, drug coated balloons, and defibrillators. Medtronic will be the partner of choice for hospitals going forward, and the Covidien deal will allow the company to continue to return at least 50% of its cash flow to shareholders via share buybacks and dividends. Read more...
T Rowe Price Buys Apple and 2 Other Companies Equity income fund reports its 2nd-quarter portfolio
The “father of growth investing,” Thomas Rowe Price founded the T Rowe Price Equity Income Fund October 1985. While Price prefers a growth-oriented approach to investing, the equity income fund invests in stocks using a “conservative, value-oriented” approach. According to its investment strategy, the fund emphasizes strong dividend payout and undervaluation. With this approach, the mutual fund can reduce its risk more than just investing in growth stocks. Read more...
IBM's CEO Discusses Cognitive Computing Under Armour, Medtronic and Softbank give examples of Watson applications
IBM (NYSE:IBM) CEO Ginni Rometty discussed Watson, IBM’s artificial intelligence platform, at this year’s Consumer Electronics Show in January. In the video below, she asserts that the future of the internet is cognitive. The goal of Watson is to help customers make better decisions by collecting massive amounts of data for predictive analytics. Three business leaders from Under Armour (NYSE:UA), Medtronic (NYSE:MDT) and Softbank (SFTBY) discuss how they are incorporating Watson’s functionality into their products and services. The video does a good job of describing IBM’s vision and business strategy. The company has had four straight years of revenue declines, and investors are wondering when new revenue streams will offset the declines in their existing businesses. Read more...
Ronald Muhlenkamp Sells Stakes in Medtronic and State Street Guru invests in ETF in 4th quarter
Ronald Muhlenkamp (Trades, Portfolio), founder and president of Muhlenkamp & Co. Inc. and portfolio manager for its mutual fund, acquired half a dozen new holdings in the fourth quarter, but his biggest transactions were divestitures. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 24.28
MDT's P/E(ttm) is ranked higher than
54% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.16 vs. MDT: 24.28 )
Ranked among companies with meaningful P/E(ttm) only.
MDT' s P/E(ttm) Range Over the Past 10 Years
Min: 10.17  Med: 20.5 Max: 54.09
Current: 24.28
10.17
54.09
Forward P/E 15.77
MDT's Forward P/E is ranked higher than
81% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 21.74 vs. MDT: 15.77 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.28
MDT's PE(NRI) is ranked higher than
53% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.53 vs. MDT: 24.28 )
Ranked among companies with meaningful PE(NRI) only.
MDT' s PE(NRI) Range Over the Past 10 Years
Min: 10.17  Med: 20.5 Max: 54.09
Current: 24.28
10.17
54.09
Price/Owner Earnings (ttm) 18.96
MDT's Price/Owner Earnings (ttm) is ranked higher than
74% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 30.39 vs. MDT: 18.96 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MDT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.24  Med: 18.96 Max: 92.5
Current: 18.96
9.24
92.5
P/B 2.03
MDT's P/B is ranked higher than
67% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. MDT: 2.03 )
Ranked among companies with meaningful P/B only.
MDT' s P/B Range Over the Past 10 Years
Min: 1.78  Med: 2.9 Max: 6.3
Current: 2.03
1.78
6.3
P/S 3.57
MDT's P/S is ranked lower than
56% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. MDT: 3.57 )
Ranked among companies with meaningful P/S only.
MDT' s P/S Range Over the Past 10 Years
Min: 1.93  Med: 3.49 Max: 6.54
Current: 3.57
1.93
6.54
PFCF 20.85
MDT's PFCF is ranked higher than
61% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.13 vs. MDT: 20.85 )
Ranked among companies with meaningful PFCF only.
MDT' s PFCF Range Over the Past 10 Years
Min: 9.19  Med: 14.78 Max: 70.14
Current: 20.85
9.19
70.14
POCF 16.79
MDT's POCF is ranked higher than
55% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 18.20 vs. MDT: 16.79 )
Ranked among companies with meaningful POCF only.
MDT' s POCF Range Over the Past 10 Years
Min: 8.14  Med: 12.86 Max: 31.21
Current: 16.79
8.14
31.21
EV-to-EBIT 20.95
MDT's EV-to-EBIT is ranked lower than
54% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.46 vs. MDT: 20.95 )
Ranked among companies with meaningful EV-to-EBIT only.
MDT' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 15.8 Max: 30.9
Current: 20.95
8.7
30.9
EV-to-EBITDA 13.99
MDT's EV-to-EBITDA is ranked higher than
54% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 16.23 vs. MDT: 13.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.4  Med: 13.3 Max: 24.8
Current: 13.99
7.4
24.8
PEG 5.85
MDT's PEG is ranked lower than
76% of the 74 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. MDT: 5.85 )
Ranked among companies with meaningful PEG only.
MDT' s PEG Range Over the Past 10 Years
Min: 1.1  Med: 1.91 Max: 18.15
Current: 5.85
1.1
18.15
Shiller P/E 25.34
MDT's Shiller P/E is ranked higher than
84% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 46.10 vs. MDT: 25.34 )
Ranked among companies with meaningful Shiller P/E only.
MDT' s Shiller P/E Range Over the Past 10 Years
Min: 14.42  Med: 22.06 Max: 42.29
Current: 25.34
14.42
42.29
Current Ratio 2.35
MDT's Current Ratio is ranked lower than
51% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. MDT: 2.35 )
Ranked among companies with meaningful Current Ratio only.
MDT' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.44 Max: 6.8
Current: 2.35
0.88
6.8
Quick Ratio 1.96
MDT's Quick Ratio is ranked higher than
52% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. MDT: 1.96 )
Ranked among companies with meaningful Quick Ratio only.
MDT' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.95 Max: 6.46
Current: 1.96
0.66
6.46
Days Inventory 143.11
MDT's Days Inventory is ranked lower than
53% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. MDT: 143.11 )
Ranked among companies with meaningful Days Inventory only.
MDT' s Days Inventory Range Over the Past 10 Years
Min: 132.14  Med: 142.57 Max: 164.01
Current: 143.11
132.14
164.01
Days Sales Outstanding 71.22
MDT's Days Sales Outstanding is ranked lower than
52% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. MDT: 71.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.41  Med: 81.9 Max: 92.09
Current: 71.22
70.41
92.09
Days Payable 66.61
MDT's Days Payable is ranked higher than
56% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. MDT: 66.61 )
Ranked among companies with meaningful Days Payable only.
MDT' s Days Payable Range Over the Past 10 Years
Min: 32.49  Med: 51.72 Max: 93.14
Current: 66.61
32.49
93.14

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.22
MDT's Dividend Yield is ranked higher than
71% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. MDT: 2.22 )
Ranked among companies with meaningful Dividend Yield only.
MDT' s Dividend Yield Range Over the Past 10 Years
Min: 0.63  Med: 1.88 Max: 2.93
Current: 2.22
0.63
2.93
Dividend Payout 0.54
MDT's Dividend Payout is ranked higher than
82% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 0.39 vs. MDT: 0.54 )
Ranked among companies with meaningful Dividend Payout only.
MDT' s Dividend Payout Range Over the Past 10 Years
Min: 0.14  Med: 0.26 Max: 1.88
Current: 0.54
0.14
1.88
Dividend Growth (3y) 13.50
MDT's Dividend Growth (3y) is ranked higher than
62% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. MDT: 13.50 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MDT' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7.6  Med: 14.9 Max: 24.9
Current: 13.5
7.6
24.9
Forward Dividend Yield 2.39
MDT's Forward Dividend Yield is ranked higher than
70% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. MDT: 2.39 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.62
MDT's Yield on cost (5-Year) is ranked higher than
78% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. MDT: 3.62 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MDT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.02  Med: 3.06 Max: 4.76
Current: 3.62
1.02
4.76
3-Year Average Share Buyback Ratio -11.30
MDT's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. MDT: -11.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.3  Med: 1 Max: 2.5
Current: -11.3
-11.3
2.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.16
MDT's Price/Projected FCF is ranked higher than
77% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 1.97 vs. MDT: 1.16 )
Ranked among companies with meaningful Price/Projected FCF only.
MDT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.41 Max: 6.95
Current: 1.16
0.76
6.95
Price/DCF (Earnings Based) 2.27
MDT's Price/DCF (Earnings Based) is ranked lower than
61% of the 18 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. MDT: 2.27 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.02
MDT's Price/Median PS Value is ranked higher than
53% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. MDT: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
MDT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.46 Max: 3.62
Current: 1.02
0.67
3.62
Earnings Yield (Greenblatt) (%) 4.72
MDT's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. MDT: 4.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.2  Med: 6.3 Max: 11.5
Current: 4.72
3.2
11.5
Forward Rate of Return (Yacktman) (%) 9.05
MDT's Forward Rate of Return (Yacktman) (%) is ranked higher than
50% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 9.23 vs. MDT: 9.05 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MDT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.2  Med: 14.3 Max: 19.5
Current: 9.05
7.2
19.5

More Statistics

Revenue (TTM) (Mil) $29,012
EPS (TTM) $ 3.01
Beta0.93
Short Percentage of Float0.88%
52-Week Range $71.03 - 89.27
Shares Outstanding (Mil)1,373.05

Analyst Estimate

Apr17 Apr18 Apr19
Revenue (Mil $) 29,743 31,150 32,552
EPS ($) 4.59 5.06 5.67
EPS w/o NRI ($) 4.59 5.06 5.67
EPS Growth Rate
(3Y to 5Y Estimate)
7.52%
Dividends Per Share ($) 1.64 1.89 2.28
» More Articles for MDT

Headlines

Articles On GuruFocus.com
52-Week Company Lows Dec 08 2016 
52-Week Company Lows Dec 01 2016 
Weekly Top Insider Buys Highlight for the Week of Nov. 25 Nov 27 2016 
Medtronic Misses 2nd Quarter Revenue Expectations Nov 27 2016 
Samuel Isaly Makes 9 New Buys in 3rd Quarter Nov 04 2016 
Dividend Aristocrats in Focus Part 23: Medtronic Oct 30 2016 
Extensive Moat Observed in Medtronic Oct 16 2016 
Barrow, Hanley, Mewhinney & Strauss Reduces Stakes in 2nd Quarter Sep 13 2016 
Dividend Aristocrat Correlation Pairs Aug 28 2016 
Jeff Auxier's Summer 2016 Market Commentary Aug 05 2016 

More From Other Websites
Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2017 Dec 09 2016
Under Trump, Congress likely to pull plug on medical device tax Dec 09 2016
Edwards Heart-Valve Guidance Lags On Medtronic, Boston Rivalry Dec 08 2016
Medtronic EVP & President Hooman Hakami to Speak at Jefferies Diabetes Technology Summit Dec 08 2016
Medtronic Hit with $17M Price-Fixing Fine in China Dec 08 2016
52-Week Company Lows Dec 08 2016
[$$] China's Medtronic Fine May Signal Health-Care-Cost Crackdown Dec 08 2016
Medtronic Teams Up with Fitbit, Accelerates Diabetic Care Dec 08 2016
China says fines Medtronic local unit 118.5 million yuan for price fixing Dec 07 2016
China says fines Medtronic local unit $17.2 mln for price fixing Dec 07 2016
Fitbit buys smartwatch maker Pebble's software assets Dec 07 2016
Medtronic and Fitbit Partner to Integrate Health and Activity Data Into New CGM Solution for... Dec 07 2016
Medtronic Endurant II/IIs Stent Graft System Wins CE Mark Dec 07 2016
China fines Medtronic $17 million on anti-monopoly charges Dec 07 2016
China fines Medtronic $17 million on anti-monopoly charges Dec 07 2016
Edwards 2017 Guidance Likely Hinges On Rivalry With Medtronic, Boston Dec 06 2016
Medtronic's Endurant(TM) II/IIs Stent Graft System Receives CE Mark for Use with ChEVAR Parallel... Dec 06 2016
MEDTRONIC PLC Files SEC form 10-Q, Quarterly Report Dec 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)